Discovery and optimization of selective inhibitors of meprin α (Part ii)

5Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Meprin α is a zinc metalloproteinase (metzincin) that has been implicated in multiple dis-eases, including fibrosis and cancers. It has proven difficult to find small molecules that are capable of selectively inhibiting meprin α, or its close relative meprin β, over numerous other metzincins which, if inhibited, would elicit unwanted effects. We recently identified possible molecular starting points for meprin α-specific inhibition through an HTS effort (see part I, preceding paper). Here, in part II, we report further efforts to optimize potency and selectivity. We hope that a hydroxamic acid meprin α inhibitor probe will help define the therapeutic potential for small molecule meprin α inhibition and spur further drug discovery efforts in the area of zinc metalloproteinase inhibition.

Cite

CITATION STYLE

APA

Wang, C., Diez, J., Park, H., Spicer, T. P., Scampavia, L. D., Becker-Pauly, C., … Bannister, T. D. (2021). Discovery and optimization of selective inhibitors of meprin α (Part ii). Pharmaceuticals, 14(3), 1–17. https://doi.org/10.3390/ph14030197

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free